文献速递肝病

单核转录组揭示重度酒精性肝炎激素反应相关肝细胞身份与免疫特征

Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis.
PubMed 文献 · J Hepatol · 2026-04-20

该研究对活检证实的重度酒精性肝炎患者(n=17)肝组织行单核RNA测序,部分患者有基线与第8天配对活检(n=8),并按Lille评分分为激素应答者(<0.45)与无应答者(≥0.45)。基线应答者S100A8+单核细胞浸润更高,无应答者成熟肝细胞标志SULT2A1表达更低且再生能力受损;基线SULT2A1阳性肝细胞≥50%强烈预测激素应答,并在多中心验证队列(n=172)中得到验证。

要点

  • 基线肝内S100A8+单核细胞比例高与激素应答相关,且第8天仍持续。
  • 无应答者成熟肝细胞身份丢失更显著、第8天循环肝细胞更少,提示再生受损。
  • 基线SULT2A1阳性肝细胞≥50%可强烈预测激素应答,或助分层治疗。

核心结论

  • 重度酒精性肝炎激素应答者与无应答者在基线即存在肝细胞和髓系细胞的差异。
  • 基线SULT2A1表达可能有助于sAH分层治疗。

研究设计与样本

  • 对活检证实的sAH患者(n=17)肝组织行单核RNA测序,其中8例有基线与第8天配对活检。
  • 按Lille评分<0.45为应答者、≥0.45为无应答者分组。
  • 另纳入酒精相关肝硬化急性失代偿患者(n=5)和健康对照(n=4)作比较。
  • 用免疫组化和空间蛋白组学在多中心验证队列(n=172)中验证。

主要发现

  • 基线时sAH-R肝内S100A8+单核细胞比例显著高于sAH-NR,第8天差异持续。
  • sAH肝内成熟肝细胞明显减少、应激和中间肝细胞群扩增,提示成熟肝细胞身份进行性丢失。
  • 该丢失在sAH-NR更明显,且第8天循环肝细胞更少,与再生能力受损一致。
  • 成熟肝细胞身份标志SULT2A1在sAH-NR基线显著降低。

关键数值与推荐

  • 基线肝活检中SULT2A1阳性肝细胞≥50%强烈预测激素应答。
  • 激素应答按Lille评分<0.45定义,无应答按≥0.45定义。

临床怎么用

  • 可用商业抗体行SULT2A1组化评分,在基线辅助预测sAH患者激素应答。
  • 结合S100A8+单核细胞浸润与肝细胞SULT2A1表达,或有助于sAH分层治疗决策。

局限性

  • 单核RNA测序发现队列样本量较小(n=17),配对活检仅8例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Severe alcohol-related hepatitis (sAH) is associated with high short-term mortality. However, 30-40% of patients fail to respond to corticosteroids, the only proven pharmacological treatment. The pathophysiological mechanisms underlying sAH and the marked heterogeneity in treatment response remain incompletely understood. We aimed to define cellular changes associated with corticosteroid response in sAH and to identify baseline markers predictive of treatment outcome. METHODS: Single-nucleus RNA sequencing was performed on liver biopsies from patients with biopsy-proven sAH (n = 17), including paired baseline and day 8 biopsies in a subset of patients (n = 8). Patients were classified as corticosteroid responders (sAH-R; Lille score <0.45) or non-responders (sAH-NR; Lille score ≥0.45). Liver biopsies from patients with acute decompensation of alcohol-related cirrhosis (AD; n = 5) and healthy controls (n = 4) were included for comparison. Findings were validated using immunohistochemistry and spatial proteomics in a large multicenter validation cohort (n = 172). RESULTS: At baseline, sAH-R exhibited a significantly higher proportion of liver-infiltrating S100A8+ monocytes compared to sAH-NR, a difference that persisted at day 8. sAH livers showed a marked reduction in mature hepatocytes and an expansion of stressed and intermediate hepatocyte populations, indicating progressive loss of mature hepatocyte identity. This loss was more pronounced in sAH-NR, who also exhibited fewer cycling hepatocytes at day 8, consistent with impaired regenerative capacity. Expression of SULT2A1, a marker of mature hepatocyte identity, was significantly reduced in sAH-NR at baseline. Finally, liver biopsies with ≥50% SULT2A1-positive hepatocytes at baseline were strongly predictive of corticosteroid response. CONCLUSIONS: This study delineates distinct immune and hepatocyte changes associated with corticosteroid response in sAH. Baseline SULT2A1 expression may facilitate stratified treatment approaches in sAH. IMPACT AND IMPLICATIONS: Severe alcohol-related hepatitis (sAH) represents one of the most devastating manifestations of alcohol-related disorders. sAH is characterized by acute hepatic inflammation and high short-term mortality. Clinical management remains challenging, as corticosteroids - the only pharmacological therapy currently applied - are ineffective in a substantial proportion of patients and are associated with significant adverse effects. These limitations highlight the need for a more detailed understanding of sAH pathophysiology and for approaches that enable improved patient stratification and therapeutic decision-making. In this study, we identify distinct pre-treatment differences between corticosteroid responders and non-responders at the level of both hepatocytes and myeloid cells, providing new insight into the cellular mechanisms underlying treatment heterogeneity in sAH. Furthermore, leveraging these findings, we developed a histology-based SULT2A1 scoring system using a commercially available antibody, which predicts corticosteroid response at baseline and may support stratified treatment approaches in clinical practice.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Van Melkebeke L, Boesch M, Ostyn T, et al. Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis. J Hepatol. 2026. PMID: 42019631. doi:10.1016/j.jhep.2026.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。